News >

Petrylak Highlights Potential of PD-1/PD-L1 Inhibitors in Bladder Cancer

Laura Panjwani
Published: Thursday, Oct 29, 2015

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

References

  1. Rosenberg J, Petrylak D, Abidoye O, et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210). Presented at: 2015 European Cancer Congress; September 25-29; Vienna, Austria. Abstract 21LBA.
  2. Plimack ER, Gupta S, Bellmunt J, et al. A phase Ib study of pembrolizumab in patients with advanced urothelial tract cancer. Presented at: ESMO 2014 Congress; September 26-30, 2014; Madrid, Spain. LBA23A.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x